SCHEDULE 13D/A: Sofinnova Funds Divest NuCana Shares, Ceasing Over 5% Beneficial Ownership
Beneficial Ownership Change
Sofinnova Venture Partners and related entities, including Dr. James I. Healy, have significantly reduced their stake in NuCana plc through multiple share dispositions and dilutive events, falling below the 5% beneficial ownership threshold.
Summary
- Sofinnova Venture Partners VIII, L.P., Sofinnova Venture Partners X, L.P., and their associated management entities, along with Dr. James I. Healy and Dr. Maha Katabi (collectively, the "Reporting Persons"), have filed Amendment No. 4 to their Schedule 13D.
- This amendment reports that the Reporting Persons are no longer beneficial owners of more than five percent (5%) of NuCana plc's securities.
- The reduction in ownership is attributed to multiple open market sales of Ordinary Shares and American Depositary Shares (ADSs) by the Reporting Persons between February 21, 2024, and June 28, 2024.
- Additionally, dilutive events resulting from NuCana plc's sales of additional Ordinary Shares since the previous Amendment No. 3 also contributed to the decrease in percentage ownership.
- As of the filing, Dr. James I. Healy retains beneficial ownership of 51,030 Ordinary Shares, representing 0.1% of the class, while other Sofinnova entities and Dr. Katabi hold 0.0%.
Sentiment
Score: 3
Explanation: The sentiment is moderately negative as a significant institutional investor has reduced its stake below the 5% threshold, indicating a substantial divestment and potentially a loss of confidence or a strategic exit from a major position. While a factual report, the underlying action is generally viewed unfavorably by the market.
Positives
- The filing provides transparency regarding the change in beneficial ownership by a significant institutional investor group.
Negatives
- A major institutional investor group, Sofinnova, has reduced its stake in NuCana plc below the 5% beneficial ownership threshold, which could be perceived negatively by the market.
- The reduction in ownership was due to both active share sales by the Reporting Persons and dilutive events from the Issuer's own share sales.
Future Outlook
The Reporting Persons state that they hold their securities for investment purposes and may, from time to time, acquire additional shares, retain, or sell all or a portion of their holdings. Any future actions will depend on factors such as share price levels, market and economic conditions, ongoing evaluation of NuCana plc's business, financial condition, operations, prospects, and alternative investment opportunities.
Industry Context
This filing is a routine disclosure of a change in beneficial ownership by a venture capital firm in a publicly traded biotechnology company. It does not provide broader industry trends or competitor analysis, focusing solely on the investment activities of the Reporting Persons in NuCana plc.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Dr. James I. Healy | NA | 2022-04-27 | Cessation of service as a director of the Issuer. |
Stakeholder Impact
- Shareholders: The reduction in a significant institutional investor's stake may lead to negative market perception and potential downward pressure on the share price.
- Company Management: The divestment by a long-term investor and former board member (Dr. Healy) could signal a shift in investor confidence or strategy.
Next Steps
- The Reporting Persons may acquire additional Ordinary Shares, retain, or sell existing holdings in the open market or privately negotiated transactions.
- Future actions will be dependent on the Reporting Persons' review of various factors including share price, market conditions, and NuCana plc's business prospects.
Key Dates
| Date | Description |
|---|---|
| 2014-04-11 | SVP VIII purchased 16,000,000 Series B convertible participating shares at £1.00 per share. |
| 2016-12-12 | Issuer granted Dr. James I. Healy options to purchase Ordinary Shares pursuant to the 2016 Share Option Scheme. |
| 2017-09-14 | Issuer completed a one-for-four reverse share split. |
| 2017-09-29 | Issuer's Prospectus filed pursuant to Rule 424(b)(4) detailing the initial public offering (IPO) and conversion of Series B Shares to Ordinary Shares. In connection with the Offering, SVP VIII purchased 666,666 ADSs at $15.00 per ADS. |
| 2019-05-15 | Issuer granted Dr. James I. Healy options to purchase 25,000 Ordinary Shares at £11.26 per share. |
| 2020-06-10 | Issuer granted Dr. James I. Healy options to purchase 47,832 Ordinary Shares at £4.78 per share. |
| 2020-09-09 | Issuer granted Dr. James I. Healy options to purchase 9,567 Ordinary Shares at £0.04 per share. |
| 2020-09-17 | Issuer filed a Prospectus Supplement detailing the Secondary Offering of 15,555,556 ADSs. In connection with this, SVP VIII purchased 1,111,111 ADSs and SVP X purchased 2,222,222 ADSs, both at $4.50 per ADS. |
| 2021-02-10 | Issuer granted Dr. James I. Healy options to purchase 23,100 Ordinary Shares at £4.53 per share and 11,550 Ordinary Shares at £0.04 per share. |
| 2021-09-09 | Dr. James I. Healy exercised options for 2,392 Ordinary Shares. |
| 2021-09-15 | Issuer granted Dr. James I. Healy options to purchase 29,700 Ordinary Shares at £1.71 per share and 14,850 Ordinary Shares at £0.04 per share. |
| 2022-04-27 | Dr. James I. Healy ceased to be a director of the Issuer. |
| 2023-12-01 | SVP VIII and SVP X began a series of open market sales of ADSs, with prices ranging from $0.3000 to $0.4200 per ADS. |
| 2024-02-20 | Last reported date of open market sales by SVP VIII and SVP X. |
| 2024-02-21 | Start date of the period during which Reporting Persons disposed of shares, leading to cessation of >5% beneficial ownership. |
| 2024-06-28 | Date of event which required the filing of this statement; Reporting Persons ceased to be beneficial owners of more than five percent (5%) of the Issuer's securities. |
| 2024-09-30 | Number of Ordinary Shares outstanding (98,630,000) used for percentage calculations, as reported by the Issuer in its Form 6-K filed on November 25, 2024. |
| 2024-11-25 | Date NuCana plc filed its Form 6-K (File No. 001-38215) reporting 98,630,000 Ordinary Shares outstanding as of September 30, 2024. |
| 2025-02-25 | Signature date of the current Schedule 13D Amendment No. 4. |
Recommendation
sellKeywords
NuCana plc, Sofinnova, Schedule 13D, Beneficial Ownership, Share Disposition, ADS, Ordinary Shares, Venture Capital, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.